Source comparison
Thymosin Alpha-1 LL-37 Protocol Immune Research: Comparison
Primary Mechanism Binds TLR-2/TLR-9, enhances dendritic cell maturation, increases IL-2 and thymulin secretion Disrupts pathogen membranes via pore formation, modulates NLRP3 inflammasome, binds FPR2 Thymosin targets adaptive immunity rebuild; LL-37 delivers d
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Binds TLR-2/TLR-9, enhances dendritic cell maturation, increases IL-2 and thymulin secretion
- Disrupts pathogen membranes via pore formation, modulates NLRP3 inflammasome, binds FPR2
- Thymosin targets adaptive immunity rebuild; LL-37 delivers direct pathogen clearance. Complementary, not redundant
- Serum Half-Life
- 2–4 hours
- 30–90 minutes
- Both require frequent dosing to maintain therapeutic effect
- Typical Research Dose
- 1.6mg subcutaneous, twice weekly
- 5–20mg subcutaneous, daily to three times weekly
- Dose frequency reflects half-life. LL-37 needs higher frequency
- Reconstitution Stability
- 28 days at 2–8°C in bacteriostatic water
- 14 days at 2–8°C in pH-adjusted solution (pH 6.5–7.0)
- LL-37 aggregates faster. Requires stricter pH control
- Clinical Trial Focus
- Chronic viral infections (HBV, HCV), post-sepsis immune recovery, cancer immunotherapy adjunct
- Biofilm infections, sepsis prevention, chronic inflammatory conditions
- Thymosin used for long-term immune reconstitution; LL-37 for acute intervention
- Bottom Line Insight
- Best for rebuilding thymic output and T-cell diversity over weeks to months
- Best for rapid pathogen clearance and acute inflammasome suppression
- Combine them for protocols addressing both immune deficiency and active infection burden